Satellos Bioscience (MSCL) AI Stock Analysis

• Market Cap: $102.26M
• Dividend Yield: N/A
• Average Volume (3M): 205.03K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.56
• Revenue Growth: N/A
• EPS Growth: -27.18%
• Country: CA
• Employees: 14
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): -0.06
• Shares Outstanding: 176,305,360
• 10 Day Avg. Volume: 72,913
• 30 Day Avg. Volume: 205,035
• PEG Ratio: N/A
• Price to Book (P/B): 1.37
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.81
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $1.25
• Price Target Upside: 81.55% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 44 Neutral
• Price Target: ―

Satellos Bioscience faces challenges typical of early-stage biotech companies, including no revenue and reliance on financing to sustain operations. Technical indicators suggest a bearish momentum. However, positive corporate developments, such as clinical trial progress and increased financing, provide a potential upside if successful commercialization ensues.

Positive Factors

Clinical Trials

The company has made significant progress, well positioning itself for the next value inflection point.

Drug Safety

Phase 1a data demonstrated that SAT-3247 was safe and well-tolerated across multiple dosage levels.

Negative Factors

Financial Performance

The company reported no revenue, in line with the consensus estimate, and a net loss.

Satellos Bioscience Business Overview & Revenue Model

Company Description

Satellos Bioscience Inc. (MSCL) is a biotechnology company focused on developing therapeutic solutions aimed at treating degenerative muscle diseases. The company operates within the healthcare sector, specifically targeting the biopharmaceutical subsector. Satellos' core product development revolves around its proprietary platform designed to identify and restore muscle stem cell function, offering potential treatments for conditions like Duchenne Muscular Dystrophy.

How the Company Makes Money

Satellos Bioscience generates revenue primarily through research and development partnerships, grants, and potential future licensing agreements for its proprietary technologies. The company collaborates with other biopharmaceutical firms and research institutions to advance its therapeutic candidates, receiving funding and milestone payments as these projects progress. Additionally, Satellos may pursue revenue through out-licensing its platform to other companies, allowing them to develop new treatments based on Satellos technology, which could result in royalties and license fees.

Satellos Bioscience Financial Statement Overview

Summary

Satellos Bioscience has no revenue and increasing operational losses. Despite a strong equity position with zero debt, the company's sustainability hinges on continued financing due to negative cash flow and operational losses.

Income Statement

Satellos Bioscience shows no revenue generation over the analyzed periods with growing negative gross profit and net income, indicating increasing operational losses. The company’s EBIT and EBITDA margins are also negative, reflecting significant operational expenses relative to non-existent revenue.

Balance Sheet

The balance sheet reflects a strong equity position with zero debt, which is positive from a financial health perspective. However, the absence of revenue challenges the sustainability of operations. The equity ratio is high, indicating reliance on equity financing, which is typical for early-stage biotechnology firms.

Cash Flow

Operating cash flow is consistently negative, illustrating ongoing cash burn without revenue offset. While the company has successfully raised financing, resulting in positive cash flow from financing activities, the free cash flow remains negative, posing a risk if financing cannot be sustained.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-20.00K	-8.82M	-3.73M	-119.92K	-48.16K
EBITDA	-28.08M	-15.71M	-8.09M	-4.60M	-1.61M
Net Income	-28.10M	-15.89M	-11.32M	-15.51M	-1.58M
Balance Sheet
Total Assets	73.02M	44.30M	6.20M	12.59M	1.13M
Cash, Cash Equivalents and Short-Term Investments	69.85M	39.59M	1.92M	4.87M	717.53K
Total Debt	0.00	0.00	0.00	0.00	1.09M
Total Liabilities	5.16M	3.62M	2.83M	2.10M	1.31M
Stockholders Equity	67.86M	40.67M	3.37M	10.48M	-183.84K
Cash Flow
Free Cash Flow	-24.98M	-14.52M	-5.79M	-5.04M	-1.66M
Operating Cash Flow	-24.98M	-14.50M	-5.78M	-5.03M	-1.66M
Investing Cash Flow	6.34M	-17.54M	-3.00K	1.74M	0.00
Financing Cash Flow	53.48M	51.03M	2.77M	7.45M	1.98M

Satellos Bioscience Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.69
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MSCL, the sentiment is Negative. The current price of 0.69 is above the 20-day moving average (MA) of 0.57, above the 50-day MA of 0.62, and below the 200-day MA of 0.73, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 46.23 is Neutral, neither overbought nor oversold. The STOCH value of 80.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:MSCL.

Satellos Bioscience Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDNA	53 Neutral	C$57.02M	―	-97.22%	―	―	-67.03%
Sector *	51 Neutral	$7.44B	0.40	-61.90%	2.33%	17.14%	1.55%
MSCL	44 Neutral	$102.26M	―	-64.18%	―	―	-27.18%
ONC	43 Neutral	$92.38M	―	-211.24%	―	―	0.10%
GLAB	35 Underperform	C$59.73M	―	98.62%	―	―	50.85%
SVA	33 Underperform	C$54.20M	―	248.46%	―	―	32.71%
ARCH	26 Underperform	C$124.28M	―	90.17%	―	―	-78.59%

Satellos Bioscience Corporate Events

Satellos Bioscience to Present at Healthcare Investor Conference

Satellos Bioscience Inc. announced its participation in the 2025 Bloom Burton & Co. Healthcare Investor Conference in Toronto, where CEO Frank Gleeson will present and engage in one-on-one meetings. This event provides an opportunity for Satellos to showcase its innovative drug, SAT-3247, which is in clinical development for treating Duchenne Muscular Dystrophy (DMD), and to highlight its MyoReGenX™ platform for discovering additional therapeutic interventions. The presentation will be available via live webcast, potentially increasing visibility and engagement with stakeholders.

Spark’s Take on TSE:MSCL Stock

According to Spark, TipRanks’ AI Analyst, TSE:MSCL is a Neutral.

Satellos Bioscience’s stock score is largely impacted by its typical startup financials, marked by a lack of revenue and reliance on financing. While the technical analysis indicates a bearish trend, recent positive corporate developments, including successful clinical trial milestones and increased funding, provide some optimism. However, the negative valuation metrics due to ongoing losses pose challenges to investor confidence.

To see Spark’s full report on TSE:MSCL stock, click here.

Satellos Bioscience to Engage with Investors at April Conferences

Satellos Bioscience Inc. announced its participation in two investor conferences in April, highlighting its ongoing efforts to engage with stakeholders and showcase its innovative drug development initiatives. The company’s involvement in these events underscores its commitment to advancing its clinical-stage drug, SAT-3247, and exploring further opportunities in muscle disease treatment, potentially strengthening its industry positioning and stakeholder relations.

Satellos Bioscience Advances DMD Therapy with Promising Trial Results

Satellos Bioscience has reported significant progress in its clinical trials for SAT-3247, a potential oral therapy for DMD. The company completed a Phase 1a trial showing safety and promising pharmacokinetic results, and has initiated a Phase 1b trial with results expected in Q2 2025. Financially, Satellos strengthened its position with a $40 million equity offering, increasing its cash reserves to $69.9 million, which is expected to support operations through 2026 and advance SAT-3247 through Phase 2 trials.

Satellos Bioscience Reports Positive Initial Data from Phase 1 Trial of SAT-3247

Satellos Bioscience has presented promising initial data from its Phase 1 trial of SAT-3247 at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference. The Phase 1a results demonstrated that SAT-3247 was safe and well-tolerated in 72 healthy volunteers, showing a favorable pharmacokinetic profile, which supports its potential as a novel oral therapy for Duchenne Muscular Dystrophy. The ongoing Phase 1b trial is enrolling adults with DMD to further assess safety and pharmacokinetics, with full data expected in Q2 2025. This development could significantly impact the treatment landscape for DMD and other muscle degeneration conditions, offering hope for improved therapeutic options.

Satellos Bioscience to Present Phase 1 Data for SAT-3247 at MDA Conference

Satellos Bioscience announced it will present its first-ever Phase 1 safety and pharmacokinetic data for SAT-3247 at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference. This presentation marks a significant milestone for Satellos, highlighting the potential of SAT-3247 as a novel treatment for Duchenne muscular dystrophy and its continued progress in clinical trials, which may enhance its position in the biotech industry.

Satellos Completes Phase 1 Enrollment for DMD Drug Trial

Satellos Bioscience Inc. has completed the enrollment of all four multiple-ascending dose cohorts for the Phase 1 clinical trial of its oral small molecule drug, SAT-3247, in healthy volunteers. This milestone is part of the company’s mission to deliver transformative therapies for degenerative diseases, specifically Duchenne muscular dystrophy (DMD), marking progress toward presenting Phase 1 data in 2025 and advancing the treatment as a potential novel therapy for muscle regeneration.